International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria - Université de Rennes Accéder directement au contenu
Article Dans Une Revue JHEP Reports Innovation in Hepatology Année : 2021

International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria

Federico Piñero
  • Fonction : Auteur
Cinzia Baccaro
  • Fonction : Auteur
Aline Lopes Chagas
  • Fonction : Auteur
Giuseppe Maria Ettorre
  • Fonction : Auteur
Jaime Poniachik
  • Fonction : Auteur
Fabrice Muscari
Fabrio Di Benedetto
  • Fonction : Auteur
Umberto Cillo
  • Fonction : Auteur
Adrián Gadano
  • Fonction : Auteur
Fernando Rubinstein
  • Fonction : Auteur
Patrizia Burra
  • Fonction : Auteur
Daniel Cherqui
  • Fonction : Auteur
Marcelo Silva
  • Fonction : Auteur

Résumé

BACKGROUND and AIMS: Good outcomes after liver transplantation (LT) have been reported after successfully downstaging to Milan criteria in more advanced hepatocellular carcinoma (HCC). We aimed to compare post-LT outcomes in patients receiving locoregional therapies (LRT) before LT according to Milan criteria and University of California San Francisco downstaging (UCSF-DS) protocol and ’all-comers’. METHODS: This multicentre cohort study included patients who received any LRT before LT from Europe and Latin America (2000-2018). We excluded patients with alpha-foetoprotein (AFP) above 1,000 ng/ml. Competing risk regression analysis for HCC recurrence was conducted, estimating subdistribution hazard ratios (SHRs) and corresponding 95% CIs. RESULTS: From 2,441 LT patients, 70.1% received LRT before LT (n = 1,711). Of these, 80.6% were within Milan, 12.0% within UCSF-DS, and 7.4% all-comers. Successful downstaging was achieved in 45.2% (CI 34.8-55.8) and 38.2% (CI 25.4-52.3) of the UCSF-DS group and all-comers, respectively. The risk of recurrence was higher for all-comers (SHR 6.01 [p <0.0001]) and not significantly higher for the UCSF-DS group (SHR 1.60 [p = 0.32]), compared with patients remaining within Milan. The all-comers presented more frequent features of aggressive HCC and higher tumour burden at explant. Among the UCSF-DS group, an AFP value of ≤20 ng/ml at listing was associated with lower recurrence (SHR 2.01 [p = 0.006]) and better survival. However, recurrence was still significantly high irrespective of AFP ≤20 ng/ml in all-comers. CONCLUSIONS: Patients within the UCSF-DS protocol at listing have similar post-transplant outcomes compared with those within Milan when successfully downstaged. Meanwhile, all-comers have a higher recurrence and inferior survival irrespective of response to LRT. Additionally, in the UCSF-DS group, an ALP of ≤20 ng/ml might be a novel tool to optimise selection of candidates for LT. CLINICAL TRIAL NUMBER: This study was registered as part of an open public registry (NCT03775863). LAY SUMMARY: Patients with more extended HCC (within the UCSF-DS protocol) successfully downstaged to the conventional Milan criteria do not have a higher recurrence rate after LT compared with the group remaining in the Milan criteria from listing to transplantation. Moreover, in the UCSF-DS patient group, an ALP value equal to or below 20 ng/ml at listing might be a novel tool to further optimise selection of candidates for LT.
Fichier principal
Vignette du fichier
pdf (24.87 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03378783 , version 1 (14-10-2021)
hal-03378783 , version 2 (14-10-2021)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Helena Degroote, Federico Piñero, Charlotte Costentin, Andrea Notarpaolo, Ilka F Boin, et al.. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. JHEP Reports Innovation in Hepatology, 2021, 3 (5), pp.100331. ⟨10.1016/j.jhepr.2021.100331⟩. ⟨hal-03378783v1⟩
45 Consultations
46 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More